ClinicalTrials.gg
CompletedNCT01806623Updated Jul 19, 2021Results posted

The Study Of Fluconazole For Vulvovaginal Candidiasis

A Phase 3 interventional study of Fluconazole in Vulvovaginal Candidiasis, sponsored by Pfizer. Completed at 10 sites in Japan. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas. However in Japan oral therapy with antifungal triazole such as Fluconazole has not been approved, and topical therapies such as vaginal tablets, pessary and cream are used clinically. The purpose of this trial is to confirm the efficacy and safety of single oral administration of fluconazole 150 mg for the treatment of vulvovaginal candidiasis in Japanese patients.

02

Conditions studied

  • Vulvovaginal Candidiasis
03

In context

Candidiasis, Vulvovaginal

109 studies on the registry are indexed under Candidiasis, Vulvovaginal; 14 are open to participants now.

This study's enrollment of 157 is above the median of 126 across 91 interventional studies indexed under Candidiasis, Vulvovaginal.

Browse Candidiasis, Vulvovaginal studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinical symptoms and signs of vulvovaginal candidiasis.
  • Patients tested positive for Candida by fungal culture.
  • Patients who can agree not to have intercourse up to 28 days after dosing.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to fluconazole.
  • Patients with severe renal dysfunction.
  • Patients with liver disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Fluconazole

    Drug: Fluconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Therapeutic Outcome: Response Rate

    Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication. Primary evaluation of therapeutic outcome was on Day 28. Response rate was calculated based on the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.

    Time frame: Day 7, Day 14 and Day 28

Secondary outcomes

  1. Clinical Efficacy: Cure Rate

    Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure rate was calculated based on the following formula, "the number of participants assessed as Cure" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

    Time frame: Day 7, Day 14 and Day 28

  2. Clinical Efficacy: Cure and Improvement Rate

    Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure and improvement rate was calculated based on the following formula, "the number of participants assessed as Cure or Improvement" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

    Time frame: Day 7, Day 14 and Day 28

  3. Mycological Efficacy: Eradication Rate

    Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate. Eradication rate was calculated based on the following formula, "the number of participants assessed as Eradication" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

    Time frame: Day 7, Day 14 and Day 28

  4. Total Scores for Clinical Symptoms

    Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome).

    Time frame: Day 1 (before dosing), Day 3, Day 7, Day 14 and Day 28

  5. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  7. Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  8. Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  9. Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  10. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight

    Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  11. Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  12. Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

  13. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

    Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

    Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing

07

Results

Posted Dec 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneFluconazole
Started157
Completed99
Not completed58
Withdrew: Withdrawal by subject1
Withdrew: Adverse event1
Withdrew: Did not meet the inclusion criteria56

Outcome measures

PrimaryTherapeutic Outcome: Response Rate

Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication. Primary evaluation of therapeutic outcome was on Day 28. Response rate was calculated based on the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.

Time frame:
Day 7, Day 14 and Day 28
Reported as:
Number · percentage of participants
Therapeutic Outcome: Response Rate
percentage of participantsFluconazole
Day 7 (n=95)33.7 (24.2 to 44.3)
Day 14 (n=100)54.2 (43.7 to 64.4)
Day 28 (n=102)74.7 (65.0 to 82.9)
SecondaryClinical Efficacy: Cure Rate

Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure rate was calculated based on the following formula, "the number of participants assessed as Cure" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

Time frame:
Day 7, Day 14 and Day 28
Reported as:
Number · percentage of participants
Clinical Efficacy: Cure Rate
percentage of participantsFluconazole
Day 7 (n=99)34.8 (25.1 to 45.4)
Day 14 (n=101)57.3 (46.8 to 67.3)
Day 28 (n=102)81.6 (72.5 to 88.7)
SecondaryClinical Efficacy: Cure and Improvement Rate

Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure and improvement rate was calculated based on the following formula, "the number of participants assessed as Cure or Improvement" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

Time frame:
Day 7, Day 14 and Day 28
Reported as:
Number · percentage of participants
Clinical Efficacy: Cure and Improvement Rate
percentage of participantsFluconazole
Day 7 (n=99)100.0 (96.1 to 100.0)
Day 14 (n=101)99.0 (94.3 to 100.0)
Day 28 (n=102)95.9 (89.9 to 98.9)
SecondaryMycological Efficacy: Eradication Rate

Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate. Eradication rate was calculated based on the following formula, "the number of participants assessed as Eradication" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.

Time frame:
Day 7, Day 14 and Day 28
Reported as:
Number · percentage of participants
Mycological Efficacy: Eradication Rate
percentage of participantsFluconazole
Day 7 (n=95)95.7 (89.5 to 98.8)
Day 14 (n=100)89.8 (82.0 to 95.0)
Day 28 (n=102)85.9 (77.4 to 92.0)
SecondaryTotal Scores for Clinical Symptoms

Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome).

Time frame:
Day 1 (before dosing), Day 3, Day 7, Day 14 and Day 28
Reported as:
Mean · score on s scale
Total Scores for Clinical Symptoms
score on s scaleFluconazole
Day 1 (before dosing, n=102)11.0 (4 to 19)
Day 3 (n=98)4.5 (0 to 12)
Day 7 (n=93)1.8 (0 to 10)
Day 14 (n=98)0.8 (0 to 7)
Day 28 (n=99)0.4 (0 to 9)
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg/mL
Maximum Observed Plasma Concentration (Cmax)
mcg/mLFluconazole
Maximum Observed Plasma Concentration (Cmax)3.71 ± 24
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursFluconazole
Time to Reach Maximum Observed Plasma Concentration (Tmax)1.9 (1.8 to 70.3)
SecondaryArea Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg*h/mL
Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)
mcg*h/mLFluconazole
Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)156.1 ± 22
SecondaryMaximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg/g
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
mcg/gFluconazole
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight1.33 ± 49
SecondaryTime to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Median · hours
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
hoursFluconazole
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight20.5 (1.8 to 116.6)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight

Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight

Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg*h/g
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
mcg*h/gFluconazole
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight79.5 ± 43
SecondaryMaximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg/mL
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
mcg/mLFluconazole
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid1.53 ± 59
SecondaryTime to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Median · hrs
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
hrsFluconazole
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid20.5 (1.8 to 116.6)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid

Time frame:
Before dosing and 2, 24, 48 and 168 hours after dosing
Reported as:
Geometric mean · mcg*h/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
mcg*h/mLFluconazole
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid85.3 ± 48

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluconazole—0/157 (0%)37/157 (23.6%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventFluconazole
NasopharyngitisInfections and infestations8/157
CystitisInfections and infestations4/157
Genital herpesInfections and infestations4/157
EczemaSkin and subcutaneous tissue disorders4/157
DiarrhoeaGastrointestinal disorders3/157
NauseaGastrointestinal disorders3/157
Genital haemorrhageReproductive system and breast disorders3/157
PyrexiaGeneral disorders2/157
BronchitisInfections and infestations2/157
PalpitationsCardiac disorders1/157

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fluconazole
Mean31.8 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Fluconazole
Female157
Male0
08

Study locations

10 sites
  • Ai WOMEN'S CLINIC
    Asahikawa, Hokkaido 070-8003, Japan
  • Shirokane Ladies' Clinic
    Minato-ku, Tokyo 108-0071, Japan
  • Takane Medical Clinic
    Shinagawa-ku, Tokyo 140-0013, Japan
  • Suzuran Clinic
    Suginami-ku, Tokyo 167-0051, Japan
  • Mori Ladies Clinic
    Fukuoka, 810-0011, Japan
  • IZUMI Ladies' Clinic
    Gifu, 502-0914, Japan
  • Tetsu-Nakamura Obstetrics and Gynecology Department Internal Medicine
    Kagoshima, 892-0845, Japan
  • Women's Clinic Kamimura
    Okayama, 700-0901, Japan
  • Sutou Ladies Clinic
    Osaka, 542-0081, Japan
  • Hayakawa Clinic
    Osaka, 542-0086, Japan
09

References and documents

Publications

  • Mikamo H, Matsumizu M, Nakazuru Y, Okayama A, Nagashima M. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. J Infect Chemother. 2015 Jul;21(7):520-6. doi: 10.1016/j.jiac.2015.03.011. Epub 2015 Mar 30. PubMed 25887336 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Nov 2013, 8 months.

Results were first posted in Dec 2014, 1 year after primary completion.

Of 15 phase 3 interventional studies under Candidiasis, Vulvovaginal, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2013
First posted
Mar 7, 2013
StartActual
Mar 5, 2013
Primary completionActual
Nov 22, 2013
CompletionActual
Nov 22, 2013
Results first posted
Dec 3, 2014
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01806623
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 7, 2013
Start date
Mar 5, 2013
Primary completion
Nov 22, 2013
Completion
Nov 22, 2013
Results posted
Dec 3, 2014
Last update
Jul 19, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion